Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Armata Pharmaceuticals, Inc. (APHB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update"
07/19/2023 8-K Quarterly results
07/11/2023 8-K Resignation/termination of a director
Docs: "CREDIT AND SECURITY AGREEMENT Credit and Security Agreement, dated as of July 10, 2023, by and among Armata Pharmaceuticals, Inc., a Washington corporation , each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto , each a “ Guarantor ” and collectively, the “ Guarantors ”) and Innoviva Strategic Opportunities LLC, a Delaware limited liability company, or an affiliate thereof, as the lender . In consideration of the premises and the covenants and agreements contained herein, the parties hereto agree as follows: ARTICLE I DEFINITIONS; CERTAIN TERMS Section 1.01.     Definitions . As used in this Agreement, the following terms shall have the respective meanings indicated below:",
"FIRST AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT",
"Amendment No. 1 to THE Second AMENDED AND RESTATED voting agreement",
"Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics"
05/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/16/2023 8-K Quarterly results
03/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis",
"NYSE American: ARMP CONFIDENTIAL 2 Forward Looking Statements This"
01/10/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Secured Convertible Credit and Security Agreement Dated as of January 10, 2023 by and among ARMATA PHARMACEUTICALS, INC., as the Borrower, EACH SUBSIDIARY OF THE BORROWER HERETO FROM TIME TO TIME, as Guarantors, and INNOVIVA STRATEGIC OPPORTUNITIES LLC, as the Lender",
"Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC"
12/19/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
09/20/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
08/11/2022 8-K Quarterly results
03/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Steve R. Martin 4503 Glencoe Avenue Marina",
"Erin Butler 4503 Glencoe Avenue Marina"
02/11/2022 8-K Quarterly results
01/05/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Brian Varnum, Chief Executive Officer Steve Martin, Chief Financial Officer January 5, 2022 NYSE American: ARMP 2 Forward Looking Statements This",
"Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs"
11/02/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OFFICE LEASE",
"Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility"
10/29/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "SECURITIES PURCHASE AGREEMENT",
"6. Facilitation of Sales Pursuant to Rule 144 . The Company shall use its commercially reasonable efforts to timely file the reports required to be filed by it under the Exchange Act or the Securities Act and the rules adopted by the Commission thereunder of the Exchange Act referred to in subparagraph of Rule 144), all to the extent required from time to time to enable the Holders to sell Registrable Securities without registration under the Securities Act within the limitations of the exemption provided by Rule 144. Upon the written request of a Holder in connection with that Holder’ s sale pursuant to Rule 144, the Company shall deliver to such Holder a written statement as to whether it has complied with such requirements. 7. Miscellaneous .",
"AMENDED AND RESTATED VOTING AGREEMENT",
"Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals"
08/12/2021 8-K Quarterly results
Docs: "Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update"
08/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/11/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events
05/14/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
01/27/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Common Stock Warrant",
"Securities Purchase Agreement, by and between the Company and Innoviva",
"Form of Amended and Restated Investors’ Rights Agreement, by and among the Company and Innoviva",
"Form of Registration Rights Agreement, by and between the Company and Innoviva",
"Form of Voting Agreement, by and between the Company and Innoviva",
"Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’ s Bacteriophage Development Programs"
01/06/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Presentation"
12/09/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors"
06/18/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections"
04/28/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Presentation",
"Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector MARINA DEL REY, California, April 28, 2020 – Armata Pharmaceuticals, Inc. , a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that Brian Varnum, Ph.D., President and Chief Development Officer, will participate in a panel discussion on non-antibiotic anti-infectives at the Maxim Group M-Vest Infectious Disease Virtual Conference to be held on May 5, 2020. The panel is scheduled to take place from 10:30 a.m. to 12:00 p.m. Eastern time. For more information, or to register, please visit: https://m-vest.com/insights/blog/Infectious-Disease-Virtual-Conference-2020 Ab..."
03/30/2020 8-K Quarterly results
03/19/2020 8-K Quarterly results
Docs: "Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update MARINA DEL REY, Calif., March 19, 2020 -- Armata Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the fourth quarter and full year 2019 and provided a corporate and clinical update. Key Fourth Quarter and Subsequent Period Highlights:"
03/19/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation"
02/26/2020 8-K Quarterly results
02/13/2020 8-K Quarterly results
01/29/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Common Stock Warrant",
"Securities Purchase Agreement, by and between the Company and Innoviva",
"Form of Investor Rights Agreement, by and the Company and Innoviva",
"Form of Voting Agreement, to be entered into by and between Innoviva and certain stockholders of the Company",
"Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy